רייאטאז 150 מ"ג Ізраїль - іврит - Ministry of Health

רייאטאז 150 מ"ג

bristol, myers squibb (israel) limited - atazanavir as sulfate 150 mg - capsules - atazanavir - reyataz is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

ברקלוד 0.5 מג Ізраїль - іврит - Ministry of Health

ברקלוד 0.5 מג

bristol - myers squibb, israel - entecavir; entecavir - טבליות מצופות פילם - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.

איקסמפרה 15 מ"ג Ізраїль - іврит - Ministry of Health

איקסמפרה 15 מ"ג

bristol-myers squibb (israel) limited - ixabepilone 15 mg - powder for concentrate for infusion - ixabepilone - ixempra is indicated for the treatment of inoperable locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy:in combination with capecitabine in patients failing prior therapy with a taxane and an anthracycline or for whom further anthracycline therapy is not indicated.as monotherapy in patients failing prior therapy with taxanes, capecitabine and anthracyclines or for whom futher anthracycline therapy is not indicated.

איקסמפרה 45 מ"ג Ізраїль - іврит - Ministry of Health

איקסמפרה 45 מ"ג

bristol-myers squibb (israel) limited - ixabepilone 45 mg - powder for concentrate for infusion - ixabepilone - ixempra is indicated for the treatment of inoperable locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy:in combination with capecitabine in patients failing prior therapy with a taxane and an anthracycline or for whom further anthracycline therapy is not indicated.as monotherapy in patients failing prior therapy with taxanes, capecitabine and anthracyclines or for whom further anthracycline therapy is not indicated.

זפוסיה 0.23 מג Ізраїль - іврит - Ministry of Health

זפוסיה 0.23 מג

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - קפסולות - ozanimod as hydrochloride 0.23 mg - ozanimod

זפוסיה 0.46 מג Ізраїль - іврит - Ministry of Health

זפוסיה 0.46 מג

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - קפסולות - ozanimod as hydrochloride 0.46 mg - ozanimod

זפוסיה 0.92 מג Ізраїль - іврит - Ministry of Health

זפוסיה 0.92 מג

bristol, myers squibb (israel) limited, israel - ozanimod as hydrochloride - קפסולות - ozanimod as hydrochloride 0.92 mg - ozanimod

רבלוזיל 25 מג Ізраїль - іврит - Ministry of Health

רבלוזיל 25 מג

bristol, myers squibb (israel) limited, israel - luspatercept - אבקה להכנת תמיסה לזריקה - luspatercept 25 mg - luspatercept

רבלוזיל 75 מג Ізраїль - іврит - Ministry of Health

רבלוזיל 75 מג

bristol, myers squibb (israel) limited, israel - luspatercept - אבקה להכנת תמיסה לזריקה - luspatercept 75 mg - luspatercept

אונורג 200 מג Ізраїль - іврит - Ministry of Health

אונורג 200 מג

bristol, myers squibb (israel) limited, israel - azacitidine - טבליות מצופות פילם - azacitidine 200 mg - azacitidine